Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Published:2018-07-10 Issue:2 Volume:138 Page:141-149
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Pradhan Aruna D.¹²,Aday Aaron W.²³,Rose Lynda M.²,Ridker Paul M²³

Affiliation:

1. Department of Medicine, Division of Cardiovascular Medicine, VA Boston Healthcare System, West Roxbury Campus, MA (A.D.P.).

2. Division of Preventive Medicine (A.D.P., A.W.A., L.M.R., P.M.R.)

3. Department of Medicine, Division of Cardiovascular Medicine (A.W.A., P.M.R.), Brigham and Women’s Hospital, Boston, MA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference22 articles.

1. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

2. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease

3. C-Reactive Protein Levels and Outcomes after Statin Therapy

4. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipids, lipid-lowering drugs and lateral epicondylitis of the humerus: a drug-targeted Mendelian randomization study;Frontiers in Genetics;2024-09-02

2. Bempedoic Acid in Secondary Prevention;American Journal of Preventive Cardiology;2024-09

3. Guizhitongluo Tablet inhibits atherosclerosis and foam cell formation through regulating Piezo1/NLRP3 mediated macrophage pyroptosis;Phytomedicine;2024-09

4. Statins, but not proprotein convertase subtilisin‐kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low‐density lipoprotein receptor upregulation;MedComm;2024-08-31

5. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease;European Heart Journal;2024-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3